These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32065362)

  • 1. Successful treatment with glecaprevir/pibrentasvir for chronic hepatitis C complicated by primary biliary cholangitis.
    Takakusagi S; Takagi H; Yokoyama Y; Marubashi K; Kizawa K; Kosone T; Sato K; Kakizaki S; Uraoka T
    Clin J Gastroenterol; 2020 Oct; 13(5):896-901. PubMed ID: 32065362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
    Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
    J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
    Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
    Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
    Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
    J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
    Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
    Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment by glecaprevir/pibrentasvir followed by hepatoprotective therapy of acute chronic hepatitis exacerbation caused by daratumumab-based regimen for multiple myeloma: Case report and review of the literature.
    Yamazaki T; Joshita S; Ichijo T; Kobayashi H; Wakabayashi SI; Yamashita Y; Sugiura A; Kawakami F; Nakazawa H; Umemura T
    J Infect Chemother; 2021 Dec; 27(12):1750-1755. PubMed ID: 34344581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
    Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
    J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
    Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
    J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
    Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
    J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
    Yap DYH; Liu KSH; Hsu YC; Wong GLH; Tsai MC; Chen CH; Hsu CS; Hui YT; Li MKK; Liu CH; Kan YM; Yu ML; Yuen MF
    Clin Mol Hepatol; 2020 Oct; 26(4):554-561. PubMed ID: 32854457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis.
    Lu M; Rupp LB; Melkonian C; Trudeau S; Daida YG; Schmidt MA; Gordon SC
    Adv Ther; 2024 Feb; 41(2):744-758. PubMed ID: 38169058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
    Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
    J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful treatment of Japanese hemophilia patient co-infected with HIV and HCV genotype 4a by glecaprevir/pibrentasvir therapy.
    Sato K; Kanayama Y; Yamazaki Y; Tojima H; Suga T; Uehara D; Kakizaki S; Yanagisawa K; Uraoka T; Ohnishi H; Okamoto H
    Clin J Gastroenterol; 2021 Dec; 14(6):1725-1732. PubMed ID: 34664197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
    Nonomura A; Tamori A; Hai H; Kozuka R; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Intern Med; 2021 Nov; 60(21):3441-3445. PubMed ID: 34024853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan.
    Liu CH; Liu CJ; Hung CC; Hsieh SM; Su TH; Sun HY; Tseng TC; Chen PJ; Chen DS; Kao JH
    Liver Int; 2020 Apr; 40(4):758-768. PubMed ID: 31710759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland.
    Müllhaupt B; Semela D; Ruckstuhl L; Magenta L; Clerc O; Torgler R; Negro F; Semmo N
    Swiss Med Wkly; 2021 Jan; 151():w20399. PubMed ID: 33516161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of glecaprevir and pibrentasvir in Saudi patients with chronic hepatitis C virus infection at a major tertiary hospital.
    Ruwayni AA; AlObary EE; Alyahya KM
    Saudi Med J; 2024 Jan; 45(1):34-39. PubMed ID: 38220241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study.
    Turnes J; Rincón D; Calleja JL; Delgado MB; Rosales JM; Andrade RJ; Manzano ML; Salmerón FJ; López MA; Calvo M; Gómez J; Molina E; Frias YN; Gálvez-Fernández RM; Vallejo-Senra N; París S; Santos de Lamadrid R; Olveira A
    Gastroenterol Hepatol; 2022 May; 45(5):342-349. PubMed ID: 34129903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
    Dore GJ; Feld JJ; Thompson A; Martinello M; Muir AJ; Agarwal K; Müllhaupt B; Wedemeyer H; Lacombe K; Matthews GV; Schultz M; Klein M; Hezode C; Mercade GE; Kho D; Petoumenos K; Marks P; Tatsch F; Dos Santos AGP; Gane E;
    J Hepatol; 2020 Mar; 72(3):431-440. PubMed ID: 31655134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.